Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437

Watchlist Manager
Harbin Gloria Pharmaceuticals Co Ltd Logo
Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437
Watchlist
Price: 2.68 CNY
Market Cap: 6.1B CNY
Have any thoughts about
Harbin Gloria Pharmaceuticals Co Ltd?
Write Note

Harbin Gloria Pharmaceuticals Co Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Harbin Gloria Pharmaceuticals Co Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437
Accounts Payable
ÂĄ66.6m
CAGR 3-Years
-33%
CAGR 5-Years
-19%
CAGR 10-Years
0%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Accounts Payable
ÂĄ163.8m
CAGR 3-Years
10%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Accounts Payable
ÂĄ470.9m
CAGR 3-Years
23%
CAGR 5-Years
13%
CAGR 10-Years
19%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Accounts Payable
ÂĄ1.4B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
15%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Accounts Payable
ÂĄ4.5B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Accounts Payable
ÂĄ307.9m
CAGR 3-Years
65%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Harbin Gloria Pharmaceuticals Co Ltd
Glance View

Market Cap
6.1B CNY
Industry
Pharmaceuticals

Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines. The company is headquartered in Beijing, Beijing and currently employs 4,769 full-time employees. The company went IPO on 2010-06-23. The firm's products include cardiovascular and cerebrovascular drugs, orthopedic drugs, nutritional drugs, anti-infective drugs, immune-enhancing drugs, diabetes drugs, antineoplastic drugs and electrolytes drugs. The firm is also engaged in the agency, research and development of pharmaceuticals, the provision of clinical services and financial investment business. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
2.32 CNY
Overvaluation 13%
Intrinsic Value
Price

See Also

What is Harbin Gloria Pharmaceuticals Co Ltd's Accounts Payable?
Accounts Payable
66.6m CNY

Based on the financial report for Sep 30, 2024, Harbin Gloria Pharmaceuticals Co Ltd's Accounts Payable amounts to 66.6m CNY.

What is Harbin Gloria Pharmaceuticals Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
0%

Over the last year, the Accounts Payable growth was -20%. The average annual Accounts Payable growth rates for Harbin Gloria Pharmaceuticals Co Ltd have been -33% over the past three years , -19% over the past five years .

Back to Top